5-(2-氯吡啶-4-基)-1,3,4-噻二唑-2-胺 | 474327-26-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-(2-氯吡啶-4-基)-1,3,4-噻二唑-2-胺
• 英文名称: 5-(2-chloropyridin-4-yl)-1,3,4-thiadiazol-2-amine
• 英文别名: 5-(2-Chloropyridin-4-YL)-1,3,4-thiadiazol-2-amine
• CAS: 474327-26-9
• 化学式: C₇H₅ClN₄S
• 分子量: 212.662
• InChiKey: TVSGIIMMTMDKRU-UHFFFAOYSA-N

物化性质

• 熔点：
  234-235 °C(Solv: acetonitrile (75-05-8))
• 沸点：
  449.1±55.0 °C(Predicted)
• 密度：
  1.539±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  92.9
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H320,H335

反应信息

• 作为反应物：
  描述：

  5-(2-氯吡啶-4-基)-1,3,4-噻二唑-2-胺 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 2.7h， 生成 tert-butyl 4-(2-(2-chloropyridin-4-yl)-5-oxo-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-yl)piperazine-1-carboxylate
  参考文献：
  名称：

  7-(piperazin-1-yl)-5H-[1,3,4]thiadiazolo[3,2-A]pyrimidin-5-ones for the treatment of thrombotic disorders

  摘要：

  本发明涉及化合物和式P的组合物，用于抑制和/或减少血小板沉积、粘附和/或聚集。变量A、B、R2、R3、R4、Ra、Ra'、Rb、Rb'、Rc、Rd、Rd'、Re和Re'的定义在公开说明书中提供。本发明还涉及用于治疗或预防血栓性疾病的方法，包括中风、心肌梗死、不稳定性心绞痛、外周血管疾病、血管成形术或支架置入后的突然闭塞以及血栓形成与血管手术有关。

  公开号：

  US09303044B2
• 作为产物：
  描述：

  2-氯异烟酸 在 吡啶 、 氯化亚砜 作用下， 生成 5-(2-氯吡啶-4-基)-1,3,4-噻二唑-2-胺
  参考文献：
  名称：

  Phenylalanine derivatives as GPR142 agonists for the treatment of Type II diabetes

  摘要：

  GPR142 is a novel GPCR that is predominantly expressed in pancreatic beta-cells. GPR142 agonists potentiate glucose-dependent insulin secretion, and therefore can reduce the risk of hypoglycemia. Optimization of our lead pyridinone-phenylalanine series led to a proof-of-concept compound 22, which showed in vivo efficacy in mice with dose-dependent increase in insulin secretion and a decrease in glucose levels. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.015

文献信息

• 7-(piperazin-1-yl)-5H-[1,3,4]thiadiazolo[3,2-A]pyrimidin-5-ones for the treatment of thrombotic disorders
  申请人：The Rockefeller University

  公开号：US09303044B2

  公开（公告）日：2016-04-05

  The present invention relates to compounds and compositions of Formula P useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The definitions of variables A, B, R2, R3, R4, Ra, Ra′, Rb, Rb′, Rc, Rd, Rd′, Re, and Re′ are provided in the disclosure. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.

  本发明涉及化合物和式P的组合物，用于抑制和/或减少血小板沉积、粘附和/或聚集。变量A、B、R2、R3、R4、Ra、Ra'、Rb、Rb'、Rc、Rd、Rd'、Re和Re'的定义在公开说明书中提供。本发明还涉及用于治疗或预防血栓性疾病的方法，包括中风、心肌梗死、不稳定性心绞痛、外周血管疾病、血管成形术或支架置入后的突然闭塞以及血栓形成与血管手术有关。
• Compounds
  申请人：Berdini Valerio

  公开号：US20100093718A1

  公开（公告）日：2010-04-15

  The invention relates to new bicyclic heterocyclic derivative compounds of Formula (I), to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer The compounds of Formula (I) are inhibitors of FGFR, VEGFR or PDGFR.

  本发明涉及一种新的双环杂环衍生物化合物，其化学式为(I)，以及包含该化合物的制药组合物和使用该化合物治疗疾病（如癌症）的方法。该化合物(I)是FGFR、VEGFR或PDGFR的抑制剂。
• PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS
  申请人：Du Xiaohui

  公开号：US20120115811A1

  公开（公告）日：2012-05-10

  Provided herein are compounds of formula I: wherein A, B, X, R 1 , R 2 and subscript n are as defined in the following disclosure. Compositions comprising the compounds are also provided, as well as methods for their use, for example, in treatment of type 2 diabetes and type 2 diabetes-related conditions.

  本文所提供的是I式化合物：其中A、B、X、R1、R2和下标n如下所述。本文还提供了包含该化合物的组合物，以及使用它们的方法，例如用于治疗2型糖尿病和2型糖尿病相关疾病的方法。
• Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
  申请人：Du Xiaohui

  公开号：US08785468B2

  公开（公告）日：2014-07-22

  Provided herein are compounds of formula I: wherein A, B, X, R1, R2 and subscript n are as defined in the following disclosure. Compositions comprising the compounds are also provided, as well as methods for their use, for example, in treatment of type 2 diabetes and type 2 diabetes-related conditions.

  本文提供的是I式化合物，其中A、B、X、R1、R2和下标n的定义如下所述。还提供了包含这些化合物的组合物，以及它们的使用方法，例如用于治疗2型糖尿病和2型糖尿病相关疾病。
• ORGANIC COMPOUNDS
  申请人：The Rockefeller University

  公开号：US20150050325A1

  公开（公告）日：2015-02-19

  The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to a drug-eluting stent comprising said compounds and methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.

  本发明涉及用于抑制和/或减少血小板沉积、粘附和/或聚集的化合物和组合物。本发明还涉及包含所述化合物的药物洗脱支架以及用于治疗或预防血栓性疾病的方法，包括中风、心肌梗塞、不稳定性心绞痛、周围血管疾病、血管成形术或支架置入后的突然闭塞和血管手术所致的血栓形成。